Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of efavirenz in metastatic castration-refractory prostate cancer
2008-002730-30Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavirenz in prostate cancer (PCa), sponsored by Institut Bergonié. Primary endpoints: Non-PSA progression rate at 3 months and PSA response rate. Started Jun 2008; status: completed.
02
Drugs
efavirenz
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-002730-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002730-30.